Paper · 19554337
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C and 16 others. Acta Neuropathol, 2009. Cited by 930 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Papers, record 19554337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19554337
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Brain Neoplasms | Major topic |
| Glioma | Major topic |
| Isocitrate Dehydrogenase | Major topic |
| Adult | |
| Age Factors | |
| Brain | |
| Cell Differentiation | |
| DNA Mutational Analysis | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Mutation | |
| Prognosis | |
| Tumor Cells, Cultured |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by576
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 930 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,947,166 | Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial. | Biomark Res | 2026 | https://conductscience.org/library/papers/42947166 | PubMed |
| 42,754,238 | Redefining care for IDH-mutant low-grade gliomas: Clinical implications of the INDIGO trial and updated guidelines. | Clin Med (Lond) | 2026 | https://conductscience.org/library/papers/42754238 | PubMed |
| 42,399,724 | Molecular characteristics of isocitrate dehydrogenase 1 R132C-mutant diffuse gliomas: association with TP53 alterations and Li-Fraumeni syndrome. | Acta Neuropathol Commun | 2026 | https://conductscience.org/library/papers/42399724 | PubMed |
| 42,198,334 | Fluorinated Derivatives of AG-881 for Positron Emission Tomography Detection of Mutated Isocitrate Dehydrogenase 1. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42198334 | PubMed |
| 42,157,737 | Golden rules for optimizing the diagnostic pathway of IDH-mutant tumors: bridging evidence and clinical practice in cholangiocarcinoma and adult-type diffuse gliomas. | Pathologica | 2026 | https://conductscience.org/library/papers/42157737 | PubMed |
| 42,079,759 | Clinical characteristics and outcomes of adult IDH-mutant brainstem gliomas: Institutional case series and systematic review. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42079759 | PubMed |
| 42,017,056 | Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42017056 | PubMed |
| 41,976,276 | Stimulated Raman Spectroscopy for Intraoperative Glioblastoma Diagnosis-A Complementary Tool to Frozen Section? | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41976276 | PubMed |
| 41,930,355 | Isocitrate Dehydrogenase-Mutant Astrocytomas: Risk Stratification and Therapeutic Advance. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41930355 | PubMed |
| 41,854,942 | Lower-grade glioma imaging volumes and survival: a single-institution analysis of 90 patients after resection using intraoperative MRI. | J Neurooncol | 2026 | https://conductscience.org/library/papers/41854942 | PubMed |
1 to 10 of 576
See all 576 cited byGenes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IDH1 | 3,417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| IDH2 | 3,418 | PubTator's text mining | https://conductscience.org/library/genes/3418 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19554337
GET https://conductscience.org/api/papers/v1/19554337/cited_by?page=2